PIPENZOLATE METHYLBROMIDE

Pipenzolate methylbromide is an antimuscarinic antispasmodic used to decrease gastric acid secretion and intestinal motility. Side effects include dry mouth, urinary retention, constipation, blurred vision, and palpitations. Only GMP materials will be supplied, logistics all according to GDP.

SKU: 18a0c14ef6df Category: Tag:

Product Description


Mechanism of Action

PIPENZOLATE METHYLBROMIDE demonstrates a broad, multilayer biochemical activity profile affecting enzymedriven catalytic pathways, receptorregulated signalling systems, mitochondrial bioenergetics, redoxstate equilibrium, ionchannel behaviour, cytoskeletal integrity and transcriptionfactor regulatory networks. Its structural features indicate potential interactions with catalytic residues, allosteric protein domains, membranebound receptors and intracellular signalling intermediates, enabling influence over phosphorylation kinetics, Ca²⁺/cAMP/IP/DAGmediated secondmessenger systems, ATP turnover, ROS buffering and mitochondrial respiratorychain performance.

Depending on concentration and biological conditions, PIPENZOLATE METHYLBROMIDE may modulate metabolic flux distribution, alter mitochondrial membrane potential, influence chromatin accessibility, impact vesicular trafficking dynamics and reshape geneexpression patterns relevant to survival, inflammation, apoptosis, autophagy, metabolic adaptation and redoxstress response.

Benefits and Advantages

This compound is widely used across advanced biochemical, pharmacological and mechanistic research domains, including:

  • Receptorligand interaction studies and affinitymapping
  • Enzymekinetic pathway deconstruction and catalyticdomain profiling
  • Mitochondrialfunction analysis and ATPflux/oxidativestress modelling
  • Multiomics integration (transcriptomics, metabolomics, proteomics, phosphoproteomics)
  • Cytoskeletalstructure and membranedynamics research
  • Autophagy, apoptosis, necroptosis and ferroptosis signalling investigations
  • SAR (structureactivity relationship) profiling and compoundoptimisation workflows
  • Pharmacodynamic modelling, thresholdactivation mapping and doseresponse scaling

Side Effects and Risks

Laboratoryobserved or predicted risks include:

  • Oxidative imbalance and excessive ROS accumulation
  • Mitochondrial overload or respiratorychain suppression
  • Dysregulation of Na⁺/K⁺/Ca²⁺ ionchannel homeostasis
  • Unintended receptor crosstalk or inhibitory interference
  • Cytoskeletal destabilisation and membrane-integrity disruption
  • Dosedependent cytotoxicity with apoptosis/autophagy activation
  • Transcriptional instability or epigenetic disturbance
  • Inflammatory signalling activation via NF-κB, MAPK or JNK pathways

Use strictly within controlled laboratory environments under appropriate biosafety protocols.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C23H30BrNO3

Molecular Weight

434.4 g/mol

CAS Number

125-51-9

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

PIPENZOLATE BROMIDE; 125-51-9; Piptal; Bromure de pipenzolate; Bromuro de pipenzolato

IUPAC/Chemical Name

(1-ethyl-1-methylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate bromide

InChl Key

XEDCWWFPZMHXCM-UHFFFAOYSA-M

InChl Code

InChI=1S/C22H28NO3.BrH/c1-3-23(2)16-10-15-20(17-23)26-21(24)22(25,18-11-6-4-7-12-18)19-13-8-5-9-14-19;/h4-9,11-14,20,25H,3,10,15-17H2,1-2H3;1H/q+1;/p-1

References

https://pubchem.ncbi.nlm.nih.gov/compound/657306;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download